[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565366":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":38,"locations":25,"responsibleParty":43,"collaborators":46,"id":48,"slug":25,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":25,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":74,"whyStopped":25,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":25},{"fullName":5,"class":6},"University of British Columbia","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"5MTHF","EXPERIMENTAL",[12],"Dietary Supplement: 5-MTHF (5-methyltetrahydrofolate)",{"label":14,"type":15,"description":16,"interventionNames":17},"Synthetic folic acid","ACTIVE_COMPARATOR","Folic acid",[18],"Dietary Supplement: Folic Acid",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Folic Acid","folic acid (0.6 mg)",[14],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"5-MTHF (5-methyltetrahydrofolate)","0.625 mg\u002Fd (6S)-5-MTHF",[9],[31,35],{"name":32,"affiliation":33,"role":34},"Crystal D Karakochuk, PhD","The University of British Columbia","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Kelsey M Cochrane, PhD","University of Saskatchewan",[39],{"name":32,"role":40,"phone":41,"phoneExt":25,"email":42},"CONTACT","604-822-0421","crystal.karakochuk@ubc.ca",{"type":34,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Crystal Karakochuk","Associate Professor, Human Nutrition",[47],{"name":37,"class":6},"100565366",false,"NCT06641245","PREconception Folic Acid Clinical Efficacy (PREFACE) Trial","PREFACE","Inclusion Criteria:\n\n* Non-pregnant females who are:\n* Currently trying to become pregnant;\n* Aged 19-42 years;\n* Low risk for an NTD-affected pregnancy\n\nExclusion Criteria:\n\n* Trying to conceive for ≥6 months (as \\~90% of pregnancies occur after 6 months of trying);\n* Diagnosed ovulatory disorders (polycystic ovary syndrome, endometriosis, or menstrual irregularity);\n* More than 2 miscarriages in the past year;\n* Undergoing fertility assistance (including current IVF or intrauterine insemination);\n* Pre-existing medical condition known to impact maternal folate status (malabsorptive and inflammatory bowel diseases, active celiac disease, gastric bypass surgery, type 1 or 2 diabetes mellitus);\n* Lifestyle factors known to impact maternal folate status (current smoking, \\>6 alcoholic drinks per week, recreational drug use);\n* On the female or male side of those trying to conceive: personal NTD history, previous NTD-affected pregnancy, or personal or family history of other folate sensitive congenital anomalies;\n* Use of folate-inhibiting medications (Chloramphenicol, Methotrexate, Metformin, Sulfasalazine, Phenobarbital, Phenytoin, Primidone, Triamterene, Barbiturates).","FEMALE","19 Years","42 Years",{"count":58,"type":59},272,"ESTIMATED","INTERVENTIONAL",[62],"NA","A study to help understand what forms of folic acid are most effective to increase folate status during pregnancy for the best protection against neural tube defects",[65,66,67,68],"Folate","Folate Bioavailability","Clinical Trials","Pregnancy",[16,65,70,71,72,73],"Methylfolate","5-MTHF","RBC Folate","Placental Growth Factor","NOT_YET_RECRUITING","2024-10-17",{"date":77,"type":78},"2024-10-21","ACTUAL",{"date":80,"type":59},"2025-01-31",{"date":82,"type":59},"2030-01-31",{"name":5,"class":6}]